Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top

18-09-2024 | Diabetes-associated Diseases | News

EASD 2024

Higher time in tight range, fewer complications

Login to get access

MedNet.nl: The higher the percentage of blood glucose values within a “tight limit range” of 3.9 to 7.8 mmol/l, the lower the number of diabetes complications. With each 10% increase in the Time In Tight Range, the risk of a microvascular complication decreased by 23.8%.

Related topics

EASD 2024 rotated-square
Type 1 Diabetes rotated-square
Diabetes Therapy rotated-square
Diabetes and Cardiac Diseases rotated-square
Diabetes and Cardiac Diseases rotated-square
Diabetic Retinopathy rotated-square
Diabetic Neuropathy rotated-square
Diabetic Neuropathy rotated-square
Circulatory Disease rotated-square
Endocrinology rotated-square

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits